Physician profile
Arkadiy Shusterman
NPI 1316992928
$2,953.28
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $304 · 2021: $517 · 2022: $604 · 2023: $224 · 2024: $343 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $668.35 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $478.86 | 2019-2025 | Linzess, Viberzi, Ubrelvy |
| Cumberland Pharmaceuticals, INC. | $307.19 | 2019-2022 | |
| Horizon Therapeutics Plc | $254.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $246.89 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $171.82 | 2019-2022 | |
| Lilly USA, LLC | $131.78 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.30 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $63.69 | 2025 | Zenpep |
| Pfizer INC. | $59.50 | 2020-2025 | |
| Ironwood Pharmaceuticals, INC | $59.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.39 | 2019-2024 | Trelegy Ellipta |
| Allergan, INC. | $44.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.51 | 2023-2024 | |
| Amgen INC. | $41.95 | 2021-2025 | Repatha, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $40.20 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $39.21 | 2023 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $39.13 | 2024 | Zoryve |
| Genentech USA, INC. | $23.42 | 2021 | |
| Lundbeck LLC | $21.95 | 2024 | Vyepti |
| Nestle Healthcare Nutrition INC. | $20.00 | 2023 | |
| Astellas Pharma US INC | $17.14 | 2019 | |
| Melinta Therapeutics, LLC | $15.63 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkadiy Shusterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.